The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

被引：0
|
作者：
La Rosee, F. [1 ,2 ]
Bremer, H. -C. [3 ]
Hochhaus, A. [4 ]
Birndt, S. [4 ]
Fellhauer, M. [5 ]
Henkes, M. [6 ]
Russo, S. G. [7 ,8 ,9 ]
La Rosee, P. [1 ,6 ]
机构：
[1] Friedrich Schiller Univ Jena, Univ Klinikum Jena, Fak Med, Jena, Germany
[2] Tech Univ Dresden, Med Fak Carl Gustav Carus, Dresden, Germany
[3] Schwarzwald Baar Klinikum, Lungenzentrum Donaueschingen, Villingen Schwenningen, Germany
[4] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[5] Schwarzwald Baar Klinikum, Apotheke Inst Klin Pharm, Villingen Schwenningen, Germany
[6] Schwarzwald Baar Klinikum, Klin Innere Med Hamatol Onkol Immunol Infekt & Pa, Villingen Schwenningen, Germany
[7] Schwarzwald Baar Klinikum, Klin Anasthesiol Intens Notfall & Schmerzmed, Villingen Schwenningen, Germany
[8] Univ Witten Herdecke, Fak Gesundheit, Witten, Germany
[9] Univ Gottingen, Fak Med, Gottingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
582
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [21] JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus
    Wenzel, Joerg
    van Holt, Nadine
    Maier, Judith
    Vonnahme, Maria
    Bieber, Thomas
    Wolf, Dominik
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (06) : 1281 - 1283
  • [22] Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids
    Sarmiento, Mauricio
    Rojas, Patricio
    Jerez, Joaquin
    Bertin, Pablo
    Campbell, James
    Garcia, Maria J.
    Pereira, Jaime
    Triantafilo, Nicolas
    Ocqueteau, Mauricio
    ACTA HAEMATOLOGICA, 2021, 144 (06) : 620 - 626
  • [23] Ruxolitinib and Severe COVID-19
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    INFECTION AND CHEMOTHERAPY, 2021, 53 (04): : 796 - 796
  • [24] Ruxolitinib in COVID-19 patients with defined hyperinflammation: The RuxCoFlam trial
    Hammersen, J.
    Birndt, S.
    Doehner, K.
    Fabisch, C.
    Weiss, M.
    Bremer, H.
    Illerhaus, G.
    Droemann, D.
    La Rosee, P.
    Hochhaus, A.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2023, 118 (05)
  • [25] Ruxolitinib in COVID-19 patients with defined hyperinflammation: the RuxCoFlam trial
    Birndt, S.
    Hammersen, J.
    Doehner, K.
    Reuken, P.
    Sauerbrey, P.
    La Rosee, F.
    Pfirrmann, M.
    Fabisch, C.
    Weiss, M.
    Traeger, K.
    Bremer, H.
    Illerhaus, G.
    Droemann, D.
    Schneider, S.
    La Rosee, P.
    Hochhaus, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 71 - 71
  • [26] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
    Gisslinger, H.
    Skrabs, C.
    Gisslinger, B.
    Schoder, R.
    Muellauer, L.
    Kralovics, R.
    HAEMATOLOGICA, 2013, 98 : 346 - 347
  • [27] The JAK1/JAK2-inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release
    Hermans, Maud A. W.
    Schrijver, Benjamin
    van Holten-Neelen, Conny C. P. A.
    Gerth van Wijk, Roy
    van Hagen, P. Martin
    van Daele, Paul L. A.
    Dik, Willem A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1412 - 1420
  • [28] Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate
    Peng, Ziyu
    Ye, Long
    Acta Crystallographica Section C: Structural Chemistry, 80 : 440 - 447
  • [29] Ruxolitinib: An effective JAK1/2 inhibitor in salvage therapy of refractory chronic GVHD
    Simonet, Marion
    Berceanu, Ana
    Daguindau, Etienne
    Desbrosses, Yohan
    Deconinck, Eric
    Larosa, Fabrice
    BONE MARROW TRANSPLANTATION, 2019, 54 : 320 - 320
  • [30] Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
    Goldsmith, Scott R.
    Rehman, Sana Saif Ur
    Shirai, Cara L.
    Vij, Kiran
    DiPersio, John F.
    BLOOD ADVANCES, 2019, 3 (23) : 4131 - 4135
12345